Introduction
============

MicroRNAs (miRNAs) are small single-stranded noncoding RNAs of \~19--25 nt in length. They regulate gene expression usually by targeting the 3′-UTR of their target mRNAs for translational repression, degradation, or both.[@b1-ott-8-2709] According to the current researches, miRNAs involved in most of the biological processes in mammal cells, including proliferation, differentiation, migration, apoptosis, malignant transformation, metabolism, and so on. It is estimated that approximately 60% genes are regulated by miRNAs.[@b2-ott-8-2709]

miRNAs were first associated with cancer in 2002,[@b3-ott-8-2709] and the expressions of miRNA-15a as well as miRNA-16-1 were found to be decreased in B-cell chronic lymphocytic leukemia, which implied their potential role in cancer diagnosis and treatment. During the following decade, the abnormal expression pattern of many miRNAs was proved,[@b2-ott-8-2709],[@b4-ott-8-2709] and gradually, miRNAs were accepted as cancer suppressors or promoters.

MicroRNA-34a (miR-34a) expression was first evaluated in malignant cholangiocytes cells in 2006.[@b5-ott-8-2709] In the next year, miR-34a was found to be directly transactivated by p53, and its responsive genes were highly enriched for those that regulate cell cycle progression, apoptosis, DNA repair, and angiogenesis.[@b6-ott-8-2709]--[@b9-ott-8-2709] In colon cancer cells, miR-34a suppressed cell proliferation and induced senescence-like phenotypes by downregulating the E2F pathway in vitro, and its decreased expression was also detected in cancer patients.[@b10-ott-8-2709] Some other researches showed the similar results,[@b11-ott-8-2709]--[@b15-ott-8-2709] so miR-34a was considered a tumor-suppressive miRNA.

In 2009, a clinical research found that miR-34a was downregulated in non-small cell lung cancer (NSCLC) tissue, and its decreased expression was correlated with a high probability of relapse (*P*=0.04), which was the first time that miR-34a was identified as a prognostic marker for cancer patients.[@b16-ott-8-2709] Up to now, overexpressed miR-34a has been reported to be related to good survival in NSCLC,[@b17-ott-8-2709] pancreatic ductal adenocarcinoma,[@b18-ott-8-2709] sinonasal squamous cell carcinoma,[@b19-ott-8-2709] Ewing's sarcoma,[@b20-ott-8-2709] mantle cell lymphoma,[@b21-ott-8-2709] mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma,[@b22-ott-8-2709] as well as glioma.[@b23-ott-8-2709] However, there were still insignificant or even opposite results.[@b24-ott-8-2709]--[@b30-ott-8-2709] Therefore, it is necessary to conduct a systematic review and meta-analysis to get a better understanding of the prognostic effect of miR-34a on cancer patients.

In this research, we collected global literatures on the prognostic effect of miR-34a on cancer patients and assessed the value of miR-34a as a biomarker for good survival.

Materials and methods
=====================

The current analysis was conducted following the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 Checklist (<http://www.prisma-statement.org/statement.htm>) and Meta-analysis of Observational Studies in Epidemiology group (MOOSE; [Table S1](#SD1-ott-8-2709){ref-type="supplementary-material"}).[@b31-ott-8-2709]

Identification of eligible studies
----------------------------------

We carefully searched the online PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) and Embase (<http://www.embase.com/home>) from January 1st 2002 to April 19th 2014 to collect related literatures. The searching details were "miR-34a (all fields) and ('neoplasms' \[MeSH terms\] or 'neoplasms' \[all fields\] or 'cancer' \[all fields\])", "miR-34a (all fields) and ('carcinoma' \[MeSH terms\] or 'carcinoma' \[all fields\])", "miR-34a (all fields) and ('tumor' \[all fields\] or 'neoplasms' \[MeSH terms\] or 'neoplasms' \[all fields\] or 'tumor' \[all fields\])", "miR-34a (all fields) and ('neoplasms' \[MeSH terms\] or 'neoplasms' \[all fields\] or 'neoplasm' \[all fields\])", in PubMed and "'mir 34a'/exp or 'mir 34a' and ('cancer'/exp or cancer)", "'mir 34a'/exp or 'mir 34a' and ('carcinoma'/exp or carcinoma)", "'mir 34a'/exp or 'mir 34a' and ('tumor'/exp or tumor)", "'mir 34a'/exp or 'mir 34a' and ('neoplasm'/exp or neoplasm)" in Embase. We set no advanced limitations when searching both the databases. All the searching results were checked by going through the titles and abstracts, and the duplications were removed directly.

The eligible studies were collected using our previous methods.[@b32-ott-8-2709] Information of the eligible reports, such as titles, abstracts, and full texts, was independently and carefully identified by three reviewers (Jian Wang, Guorong Dan, and Feng Ye), and these extracted articles were checked for a second time by two reviewers (Yu Ding and Jin Cheng). All disagreements were discussed by the aforementioned reviewers or in consultation with two senior reviewers (Fahuan Yuan and Zhongmin Zou).

Quality assessment
------------------

All the included studies for survival analysis were evaluated according to the critical review checklist of the Dutch Cochrane Centre proposed by MOOSE.[@b31-ott-8-2709] As described in detail previously,[@b32-ott-8-2709] studies were excluded if they did not mention all the seven points.

Data extraction and conversion
------------------------------

Data were extracted in standardized data collection form. With regard to the researches on the prognostic effect of miR-34a on cancer survival, the extracted data included the following details: 1) publication information as mentioned earlier; 2) patient characteristics, including sample size, type of disease, stage of disease, histological type, and follow-up time; 3) miR-34a measurement and cutoff value; and 4) hazard ratios (HRs) of elevated miR-34a for overall survival (OS), disease-free survival, disease-specific survival (DSS), event-free survival (EFS), progress-free survival, recurrence-free survival, as well as their 95% confidence intervals (CIs) and *P*-values. If available, the HRs with their 95% CIs and *P*-values were directly collected from the original articles or Email correspondence with the corresponding authors. If not, the HRs and their 95% CIs were calculated using the data of observed deaths/cancer recurrences, the data of samples in each group, or the data provided by the authors. If only Kaplan--Meier curves were available, essential data were extracted from the graphical survival plots and the HRs were estimated. All the aforementioned calculations were based on the methods provided by Parmar et al[@b33-ott-8-2709] and Tierney et al[@b34-ott-8-2709] which we used in our previous meta-analysis.[@b32-ott-8-2709]

Statistical analysis
--------------------

The test of heterogeneity of combined HRs was carried out using Cochran's *Q* test and Higgins *I*-squared statistic. The factors contributing to the heterogeneities were analyzed by subgroup analysis or sensitive analysis according to our previous methods.[@b32-ott-8-2709] Publication bias was evaluated using the funnel plot with the Egger's bias indicator test.[@b35-ott-8-2709] The other details were described in our previous analysis.[@b32-ott-8-2709] All analyses were performed using "STATA: Data Analysis and Statistical Software" V11.

Results
=======

Study characteristics and systematic review
-------------------------------------------

We collected 1,005 records from PubMed and 2,986 from Embase in the primary research with different keywords and excluded 3,015 duplicates from the initial records. After screening the titles, abstracts, publication types, and full texts of the remaining 1,005 records, 990 records were excluded according to the listed criteria. Then, the references of the remaining 15 qualified records were manually checked, and there was no additional record found in the cross-references. So, we got the 15 records included in our analysis.[@b16-ott-8-2709]--[@b30-ott-8-2709] [Figure 1](#f1-ott-8-2709){ref-type="fig"} showed the flow diagram of candidate selection records in our study.

All the 15 studies were retrospective cohort researches in design. The collected 2,597 patients were from Austria, Belgium, Brazil, People's Republic of China, Finland, France, Germany, Greece, Italy, Japan, Lithuania, Poland, Romania, Slovakia, Spain, Sweden, UK, US, and Yugoslavia. The sample sizes ranged from 24 to 884 with an average sample size of 173 per study. The patients were diagnosed with a variety of cancers, including acute myeloid leukemia with complex karyotype, glioma, leukemic mantle cell lymphoma, resectable pancreatic ductal adenocarcinoma, glioblastoma, NSCLC, breast cancer, sinonasal squamous cell carcinoma, Ewing's sarcoma of bone, gastric cancer, esophageal adenocarcinoma, ovarian cancer, gastric mucosa-associated lymphoid tissue lymphoma, and diffuse large B-cell lymphoma. Of all the 15 studies, four studies focused on digestive system tumor (n=351),[@b18-ott-8-2709],[@b22-ott-8-2709],[@b28-ott-8-2709],[@b29-ott-8-2709] three studies on NSCLC (n=742),[@b16-ott-8-2709],[@b17-ott-8-2709],[@b24-ott-8-2709] two studies on glioma (n=302),[@b23-ott-8-2709],[@b26-ott-8-2709] and two studies on lymphoma (n=152).[@b21-ott-8-2709],[@b22-ott-8-2709] Ten of the studies provided the stage of cancer patients, while the remaining five records did not. Thirteen of the 15 studies detected the expression of miR-34a in cancer tissue (six frozen and seven formalin fixed and paraffin embedded), one study detected in blood sample,[@b29-ott-8-2709] and one study mentioned nothing about the concerning information.[@b26-ott-8-2709] Six of the included studies used median value as cutoff value,[@b18-ott-8-2709],[@b20-ott-8-2709],[@b24-ott-8-2709],[@b25-ott-8-2709],[@b27-ott-8-2709],[@b29-ott-8-2709] three studies used exact value of miRNA expression,[@b17-ott-8-2709],[@b19-ott-8-2709],[@b23-ott-8-2709] two studies used values selected by Maxstat software,[@b16-ott-8-2709],[@b21-ott-8-2709] one study used the first quartile of the Automated Quantitative Analysis score distribution,[@b26-ott-8-2709] and three did not mention the concerning information. For criteria of survival assessment, ten of the included studies used OS, two used recurrence-free survival, two used progress-free survival, two used disease-free survival, one used DSS, one used cancer-specific survival, and one used EFS. The HRs were acquired by direct collection of reported data in six records, calculation based on the shown data in three records, evaluation from the survival curve in five researches, and author's Email for one research. The follow-up time ranged from 23 to 150 months and reached 5 years in ten studies. The main information of the 15 studies was summarized in [Table 1](#t1-ott-8-2709){ref-type="table"}.

To measure the expression of miR-34a, 12 of the 15 studies used qRT-PCR, two used in situ hybridization,[@b22-ott-8-2709],[@b28-ott-8-2709] and one used microarray.[@b30-ott-8-2709] In the qRT-PCR studies, three used U6B as their internal reference,[@b17-ott-8-2709],[@b23-ott-8-2709],[@b25-ott-8-2709] three used U6,[@b18-ott-8-2709],[@b20-ott-8-2709],[@b22-ott-8-2709] and miR-16,[@b29-ott-8-2709] miR-191,[@b16-ott-8-2709] U44,[@b19-ott-8-2709] U48,[@b21-ott-8-2709] U66,[@b24-ott-8-2709] or TBP[@b27-ott-8-2709] was used in one study separately. With regard to risk evaluation methods, five researches used Kaplan--Meier curves and the rest ten researches used Multiple Cox proportional hazard model. Seven of the 15 researches collected their cancer samples after a period of treatment, seven researches declared that their samples were collected before any clinical treatment, and the rest one research neglected the related information. All the assay details were summarized in [Table 2](#t2-ott-8-2709){ref-type="table"}.

Meta-analysis results
---------------------

HRs could only be retrieved from the unique study, such as DSS (HR =0, 95% CI: 0) in sinonasal squamous cell carcinoma, cancer-specific survival in breast cancer (5-year HR =0.88, 0.65--1.88, *P*=0.573; 10-year HR =0.67, 95% CI: 0.50--0.89, *P*=0.073), and EFS (HR =0.491, 95% CI: 0.40--0.60, *P*=0.0004). If more than two researches fall into one category, the HRs were pooled. For studies evaluating OS of patients, a pooled HR and its 95% CI were calculated with a random model because of the high heterogeneity between studies (*P*=0.000, *I*^2^=79.4%). The result showed that higher expression of miR-34a may predict good OS, and the pooled HR was 0.76 (95% CI: 0.55--1.06); however, the effect did not reach the level of statistical significance (*P*=0.105) ([Figure 2](#f2-ott-8-2709){ref-type="fig"}).

Furthermore, subgroup analysis was carried out based on the types of cancers, such as digestive system cancer, lymphoma, and sarcoma. First, as an obvious heterogeneity (*P*=0.002 and *I*^2^=84.0%) existed in those researches on OS of digestive system cancer patients, a random model was used to pool the HRs. The combined HR, 0.51 (95% CI: 0.20--1.26, *P*=0.145) ([Figure 3A](#f3-ott-8-2709){ref-type="fig"}), indicated that overexpressed miR-34a would potently predict good OS for patients with digestive system cancer. Two researches focused on the prognostic effect of miR-34a on the OS of lymphoma patients and sarcoma patients separately, and meta-analysis was not conducted.

Seeing that the expression of miR-34a in some researches was detected in cancer samples collected before treatment, and some was after treatment, HRs was also pooled according to these two conditions. A random model was used to pool the HRs of researches with untreated patients (low heterogeneity, *P*=0.060 and *I*^2^=59.5%), and the combined HR was 0.63 (95% CI: 0.38--1.06, *P*=0.084) ([Figure 4A](#f4-ott-8-2709){ref-type="fig"}). Because an obvious heterogeneity (*P*=0 and *I*^2^=84.4%) existed among six researches with treated patients, a random model was used to pool the HRs. The combined HR, 0.79 (95% CI: 0.51--1.21, *P*=0.271) ([Figure 4B](#f4-ott-8-2709){ref-type="fig"}), was comparable with the pooled HR of untreated patients, suggesting that the treatment did not significantly influence the predictive effect of miR-34a.

Possible sources of the heterogeneity
-------------------------------------

Obvious heterogeneity of subjects was found in all the four analysis groups (OS for all, *P*=0 and *I*^2^=74.9%; OS for digestive system cancer, *P*=0.004 and *I*^2^=77.7%; OS for treated patients, *P*=0 and *I*^2^=84.4%; and OS for untreated patients, *P*=0.060 and *I*^2^=59.5%). The most possible sources of the heterogeneity were also analyzed by different methods.

On the one hand, since the heterogeneity of OS analysis group was obvious, we divided the 11 studies into three cancer type-specific analysis groups (four studies on digestive system cancer, two studies for lymphoma, and two studies on sarcoma). The heterogeneity was still obvious in digestive system cancer and sarcoma groups, so the cancer type could not solely explain the heterogeneity in OS analysis group. On the other hand, a meta-regression analysis was conducted to evaluate the potential factors responsible for the obvious heterogeneity. As a result, the publication year (*P*=0.617), cutoff values (*P*=0.651), patient's origin (*P*=0.914), risk evaluation method (*P*=0.957), follow-up time (*P*=0.751), and cancer type (*P*=0.112) contributed little to the heterogeneity, but the sample size (*P*=0.023) was the main source of heterogeneity.

Because meta-regression analysis is not proper to seek the sources of heterogeneity for analysis group with less than ten studies, sensitivity analysis was performed instead. In the OS analysis group for untreated patients, heterogeneity was significant (*P*=0.060 and *I*^2^=59.5%). When Nakatani's study was removed from analysis, the heterogeneity became insignificant (*P*=0.704 and *I*^2^=0%). Using the same method, we found that Jamieson's studies were responsible for the heterogeneity in the digestive system cancer analysis group, and Jamieson's as well as He's studies contributed most to the heterogeneity in the treated patients group.

Publication bias
----------------

The publication bias of included studies was evaluated by funnel plots and Egger's tests. As shown in [Figure 3B](#f3-ott-8-2709){ref-type="fig"}, the funnel plots were almost symmetric. In OS meta-analysis, the *P*-values of Egger's regression intercepts were 0.175. Hence, there was no evidence for significant publication bias in our meta-analysis.

Discussion
==========

miR-34 family includes three members--miR-34a, miR-34b, and miR-34c. In human, miR-34a is located at 1p36 locus of chromosome 1, and miR-34b and miR-34c are located at 11q23 locus of chromosome 11. All the three members are p53-dependent and share the same seed sequence as well as similar functions, but their target genes are different.[@b36-ott-8-2709] As a downstream element of p53 pathway, miR-34a is always known as a tumor-suppressive miRNA for its repression effect on cell cycle, cell invasion, cell migration, cancer stem cell, and so on.[@b37-ott-8-2709] miR-34a plays an important role in DNA damage response. Ectopic expression of miR-34a induces cell cycle arrest by downregulating target genes, and as a result, inhibits damaged DNA replication.[@b6-ott-8-2709],[@b10-ott-8-2709] The expression of miR-34a decreases frequently in some p53 mutant cancer cells, such as U251 and chronic lymphocytic leukemia cells. In these cells, some miR-34a target genes, which are related to cell cycle, tumor invasion, and migration, are upregulated,[@b39-ott-8-2709],[@b40-ott-8-2709] and restoration of functional miR-34a enhances the chemotherapy susceptibility and inhibits tumor cell growth. Some of the direct downstream targets of miR-34a, such as Bcl-2, Notch, and HMGA2 (high-mobility group AT-hook 2), are all responsible for self-renewal of the cell, so miR-34a may suppress the self-renewal of cancer stem cells.[@b36-ott-8-2709],[@b41-ott-8-2709]

In animal tumor models, the therapeutic activity of miR-34a was also evaluated in NSCLC, prostate cancer, melanoma, pancreatic cancer, and lymphoma, and the miR-34a treated animal showed a significant tumor growth inhibition.[@b37-ott-8-2709] These experiment results were consistent to our research.

In the current analysis, we got four pooled HRs from 15 researches on 2,597 patients with 13 different types of cancer from 19 countries. The main conclusions can be summarized as follows: 1) miR-34a did predict good overall survival for cancer patients with a pooled HR =0.76 (95% CI: 0.55--1.06), though the *P*-value was not satisfying enough (*P*=0.105); 2) the result seemly suggested that miR-34a was an ideal biomarker for good outcome in digestive system cancer patients (HR =0.50, 95% CI: 0.25--0.99, *P*=0.048); 3) the predictive role of miR-34a in cancer tissue collected from patients before (HR =0.63, 95% CI: 0.38--1.06, *P*=0.084) and after (HR =0.79, 95% CI: 0.51--1.21, *P*=0.271) treatment, and they were not obviously different. To our knowledge, this was the first meta-analysis on the prognostic effect of miR-34a on cancer patients.

Though the prognostic effect role of miR-34a on cancer patients was proved by experimental results and statistically identified by clinical researches and this meta-analysis, current conclusions should be cautiously appreciated. First, all the four pooled HRs were of statistical insignificance, suggesting the predictive effect of miR-34a was limited. Second, several HRs were calculated based on the data collected from the survival curves, which would bring errors, although small. Third, HRs were pooled from different articles with different cutoff values due to methods limitations while a general baseline of miR-34a expression level could not be set up. In addition, the HR for OS in Mudduluru's study was 0.01 with 95% CI of 0, which made the direct pooling of this HR with the others using STATA impossible, so the HRs were pooled without Mudduluru's study. Fourth, only researches published in English were included in this analysis, which could lead to the miss of applicable studies in non-English publication.

Because six of the eight analysis groups were with heterogeneity, the HRs were pooled with a random effect model, and the possible resource of heterogeneity was also explored by subgroup analysis, meta-regression, and sensitive analysis. Subgroup analysis based on cancer types as well as the meta-regression result suggested that the cancer type might not be responsible for the heterogeneity. The meta-regression results showed that the sample size of each study was responsible for the obvious heterogeneity in OS analysis group, and the sensitive analysis results figured out responsible studies of heterogeneity in the analysis groups of treated patients, untreated patients, and digestive system cancer patients. Publication bias was not found in the OS analysis group; however, the amount of researches was not large enough to ensure the current conclusion.

Nowadays, miRNAs have been widely considered as oncogene or cancer suppressor, but several concerns should be stressed. First, a set of miRNAs would be more proper to predict the outcome of one type of cancer. There are already studies focused on this issue,[@b42-ott-8-2709],[@b43-ott-8-2709] and present analysis proposes miR-34a as a candidate miRNA for future study. Second, most of the studies detected the expression of miR-34a in cancer tissue, and this brings many problems. Due to the heterogeneity of cancer, the collected tissue might not precisely reflect the status of cancer, and lack of standard methods of collecting the tissue, isolating the RNA, detecting the expression of miRNA, and even the internal references would obstruct the clinical research of miRNA in cancer. Third, circulating miRNAs would be an ideal choice for their convenient sampling in future clinical cancer research. Circulating miRNA may not only play diagnostic and prognostic role in cancer patients but also can be applied in cancer screening by regularly monitoring miRNA profiles.

Conclusion
==========

Our meta-analysis collected studies on the relationship of miR-34a expression and cancer patient survival found that the overexpression of miR-34a potently predict good survival of patients with digestive system cancer. Because of the limitation of meta-analysis results when applied to observational or retrospective studies that could hardly be compared, one should be cautious in interpreting the current conclusion. Further clinical researches are needed to testify the association between miR-34a and cancer prognosis as well as the efficiency of therapies.

Supplementary materials
=======================

###### 

MOOSE checklist

  Checklist items                                                                                                                                                                                                                                                                Related sections and indications
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
  **Reporting of background should include**                                                                                                                                                                                                                                     
  Problem definition                                                                                                                                                                                                                                                             Background
  Hypothesis statement                                                                                                                                                                                                                                                           Background
  Description of study outcome(s)                                                                                                                                                                                                                                                OS, DFS, PFS, RFS, DSS, EFS, CSS
  Type of exposure or intervention used                                                                                                                                                                                                                                          Cancer
  Type of study designs used                                                                                                                                                                                                                                                     Systematic reviews and meta-analysis
  Study population                                                                                                                                                                                                                                                               Global
  **Reporting of search strategy should include**                                                                                                                                                                                                                                
  Qualifications of searchers (eg, librarians and investigators)                                                                                                                                                                                                                 Stated in methods
  Search strategy, including time period included in the synthesis and keywords                                                                                                                                                                                                  Methods
  Effort to include all available studies, including contact with authors                                                                                                                                                                                                        We contact authors and searched reference lists and citations
  Databases and registries searched                                                                                                                                                                                                                                              Methods
  Search software used, name and version, including special features used (eg, explosion)                                                                                                                                                                                        360 secured browser 6.2
  Use of hand searching (eg, reference lists of obtained articles)                                                                                                                                                                                                               Methods
  List of citations located and those excluded, including justification                                                                                                                                                                                                          Flow diagram in [Figure 1](#f1-ott-8-2709){ref-type="fig"}
  Method of addressing articles published in languages other than English                                                                                                                                                                                                        Method
  Method of handling abstracts and unpublished studies                                                                                                                                                                                                                           Method
  Description of any contact with authors                                                                                                                                                                                                                                        Method
  **Reporting of methods should include**                                                                                                                                                                                                                                        
  Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested                                                                                                                                                                     Method
  Rationale for the selection and coding of data (eg, sound clinical principles or convenience)                                                                                                                                                                                  Methods
  Documentation of how data were classified and coded (eg, multiple raters, blinding, and interrater reliability)                                                                                                                                                                Methods
  Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)                                                                                                                                                                               Methods
  Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results                                                                                                                                     Methods
  Assessment of heterogeneity                                                                                                                                                                                                                                                    Methods
  Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated   Methods
  Provision of appropriate tables and graphics                                                                                                                                                                                                                                   Methods
  **Reporting of results should include**                                                                                                                                                                                                                                        
  Graphic summarizing individual study estimates and overall estimate                                                                                                                                                                                                            [Figures 2](#f2-ott-8-2709){ref-type="fig"}, [3](#f3-ott-8-2709){ref-type="fig"}
  Table giving descriptive information for each study included                                                                                                                                                                                                                   [Tables 1](#t1-ott-8-2709){ref-type="table"}, [2](#t2-ott-8-2709){ref-type="table"}
  Results of sensitivity testing (eg, subgroup analysis)                                                                                                                                                                                                                         [Figures 4](#f4-ott-8-2709){ref-type="fig"}
  Indication of statistical uncertainty of findings                                                                                                                                                                                                                              Discussion
  **Reporting of discussion should include**                                                                                                                                                                                                                                     
  Quantitative assessment of bias (eg, publication bias)                                                                                                                                                                                                                         Result
  Justification for exclusion (eg, exclusion of non-English language citations)                                                                                                                                                                                                  Discussion
  Assessment of quality of included studies                                                                                                                                                                                                                                      Results and discussion
  **Reporting of conclusions should include**                                                                                                                                                                                                                                    
  Consideration of alternative explanations for observed results                                                                                                                                                                                                                 Discussion
  Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)                                                                                                                                                      Discussion
  Guidelines for future research                                                                                                                                                                                                                                                 Discussion
  Disclosure of funding source                                                                                                                                                                                                                                                   Acknowledge

**Abbreviations:** OS, overall survival; DFS, disease-free survival; PFS, progress-free survival; RFS, recurrence-free survival; DSS, disease-specific survival; CSS, cancer-specific survival; MOOSE, Meta-analysis of Observational Studies in Epidemiology group.
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![The flowchart showed the selection of studies for meta-analysis.\
**Abbreviation:** miR-34a, microRNA-34a.](ott-8-2709Fig1){#f1-ott-8-2709}

![Forrest plots of studies evaluating hazard ratios of high miR-34a expression. The random effects analysis model showed the pooled HR for overall survival is 0.76 with 95% CI: 0.55--1.06, and *P*-value is 0.105.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; miR-34a, microRNA-34a; OS, overall survival; HR, hazard ratio; ID, identification.](ott-8-2709Fig2){#f2-ott-8-2709}

![Forrest plots of studies evaluating hazard ratios of high miR-34a expression and Funnel plots of studies included in meta-analysis.\
**Notes:** (**A**) The random effects analysis model showed the pooled HR for digestive system cancer patients overall survival is 0.51 with 95% CI: 0.20--1.26, and *P*-value is 0.146. (**B**) Funnel plots of studies assessed the prognostic effect of miR-34a on overall survival. Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; miR-34a, microRNA-34a; OS, overall survival; HR, hazard ratio; SE, standard error; ID, identification.](ott-8-2709Fig3){#f3-ott-8-2709}

![Subgroup analysis results.\
**Notes:** (**A**) The random effects analysis model showed the pooled HR for overall survival of untreated patients is 0.63 with 95% CI: 0.38--1.06, and *P*-value is 0.084. (**B**) The random effects analysis model showed the pooled HR for overall survival of treated patients is 0.79 with 95% CI: 0.51--1.21, and *P*-value is 0.271. Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; OS, overall survival; HR, hazard ratio; ID, identification.](ott-8-2709Fig4){#f4-ott-8-2709}

###### 

Summary table of meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Year   Origin of population         Study design   Diseases                                      N     Stage     Sample           Cutoff                                          Survival analysis   Hazard ratios   Follow-up time (months)
  ---------------------------------- ------ ---------------------------- -------------- --------------------------------------------- ----- --------- ---------------- ----------------------------------------------- ------------------- --------------- -------------------------
  Gallardo et al[@b16-ott-8-2709]    2009   Spain                        R              NSCLC                                         70    I--III    FFPE tissue      Selected by the maxstat package of R            SC                  RFS             38 (1--127)

  Voortman et al[@b24-ott-8-2709]    2010   14 countries                 R              NSCLC                                         636   I--III    FFPE tissue      Median                                          RE                  OS              96

  Jamieson et al[@b18-ott-8-2709]    2012   UK                           R              Resectable pancreatic ductal adenocarcinoma   48    II--III   Frozen tissue    Median                                          RE                  OS              Median 23.9

  Peurala et al[@b30-ott-8-2709]     2011   Finland                      R              Breast cancer                                 884   I--IV     Tissue           --                                              RE/CA               CSS             Up to 120

  Hu et al[@b28-ott-8-2709]          2011   US                           R              Esophageal adenocarcinoma                     99    --        FFPE tissue      --                                              RE                  OS, DFS         16.25 (0.37--256.43)

  Reimer et al[@b27-ott-8-2709]      2011   Austria                      R              Ovarian cancer                                130   I--IV     FFPE tissue      Median                                          RE                  OS, PFS         23.5 (10.0--91.0)\
                                                                                                                                                                                                                                                           45.0 (20.8--108.3)

  Mudduluru et al[@b17-ott-8-2709]   2011   Italy                        R              NSCLC                                         36    I--III    Frozen tissue    0.75                                            SC                  OS              Up to 45

  Genovese et al[@b26-ott-8-2709]    2012   US                           R              Glioblastoma                                  220   --        --               First quartile of the AQUA score distribution   SC                  OS              Up to 112

  Ogawa et al[@b19-ott-8-2709]       2012   Japan                        R              Sinonasal SCC                                 24    II--IVA   Tissue           0.43                                            RE                  DFS, DSS        53 (15--97)

  Nakatani et al[@b20-ott-8-2709]    2012   Italy                        R              Ewing's sarcoma of bone                       49    --        Frozen tissue    Median                                          RE/CA               OS, EFS         88 (26--217)

  Rücker et al[@b25-ott-8-2709]      2013   Germany                      R              AML with complex karyotype                    85    --        Frozen samples   Median                                          RE                  OS, RFS         Up to 52

  Navarro et al[@b21-ott-8-2709]     2013   Spain, Germany, US           R              Leukemic MCL                                  30    --        Tissue           Maxstat software                                SC                  OS              150

  He et al[@b22-ott-8-2709]          2013   People's Republic of China   R              Gastric MALT lymphoma and DLBCL               122   II--IV    Frozen tissue    --                                              RE/CA               OS              63 (3--123)

  Gao et al[@b23-ott-8-2709]         2013   People's Republic of China   R              Glioma                                        82    III--IV   Frozen tissue    2^∧^-DCt =1                                     SC                  OS, PFS         23 (3--72)

  Huang et al[@b29-ott-8-2709]       2014   People's Republic of China   R              Gastric cancer                                82    IV        Blood samples    Median                                          AP                  OS              Median 8.2
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** The 14 countries are as follows: Austria, Belgium, Brazil, France, Germany, Greece, Italy, Lithuania, Poland, Romania, Slovakia, Spain, Sweden, and Yugoslavia.

**Abbreviations:** AML, acute myeloid leukemia; AP, author provided; CA, calculate; CSS, cancer-specific survival; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; DSS, disease-specific survival; EFS, event-free survival; FFPE, formalin-fixed and paraffin-embedded; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progress-free survival; RE, reported; RFS, recurrence-free survival; SCC, squamous cell carcinoma; SC, survival curve.

###### 

Summary table of miRNA detection, the HRs and their 95% CIs

  Author                             Year   Disease                                       HRs     95% CI and *P*-values       Outcome       miR-34a detection   Internal reference   Risk evaluation method   Before or after treatment
  ---------------------------------- ------ --------------------------------------------- ------- --------------------------- ------------- ------------------- -------------------- ------------------------ ---------------------------
  Ogawa et al[@b19-ott-8-2709]       2012   Sinonasal SCC                                 0       0                           DSS           qRT-PCR             U44                  Cox model                Before
  Ogawa et al[@b19-ott-8-2709]       2012   Sinonasal SCC                                 0.005   0--0.29, *P*=0.011          DFS           qRT-PCR             U44                  Cox model                Before
  Mudduluru et al[@b17-ott-8-2709]   2011   NSCLC                                         0.01    0                           OS            qRT-PCR             U6B                  Kaplan--Meier            Before
  Jamieson et al[@b18-ott-8-2709]    2012   Resectable pancreatic ductal adenocarcinoma   0.15    0.06--0.37, *P*=0.0128      OS            qRT-PCR             U6                   Cox model                After
  Nakatani et al[@b20-ott-8-2709]    2012   Ewing's sarcoma                               0.385   0.24--0.60, *P*=0.0000245   OS            qRT-PCR             U6                   Cox model                Before
  He et al[@b22-ott-8-2709]          2013   Gastric MALT lymphoma and DLBCL               0.44    0.21--0.90, *P*=0.043       OS            qRT-PCR             U6                   Cox model                After
  Gallardo et al[@b16-ott-8-2709]    2009   NSCLC                                         0.47    0.20--1.21, *P*=0.043       RFS           qRT-PCR             miR-191              Kaplan--Meier            After
  Nakatani et al[@b20-ott-8-2709]    2012   Ewing's sarcoma                               0.491   0.40--0.60, *P*=0.0004      EFS           qRT-PCR             U6                   Cox model                Before
  Navarro et al[@b21-ott-8-2709]     2013   Leukemic MCL                                  0.61    0.01--26.26, *P*=0.008      OS            qRT-PCR             RU48                 Kaplan--Meier            Before
  Peurala et al[@b30-ott-8-2709]     2011   Breast cancer                                 0.67    0.50--0.89, *P*=0.073       10-year CSS   Microarray          --                   Cox model                Before
  Hu et al[@b28-ott-8-2709]          2011   Esophageal adenocarcinoma                     0.71    0.41--1.24, *P*=0.23        OS            ISH                 --                   Cox model                Before
  Hu et al[@b28-ott-8-2709]          2011   Esophageal adenocarcinoma                     0.72    0.43--1.22, *P*=0.22        DFS           ISH                 --                   Cox model                Before
  Gao et al[@b23-ott-8-2709]         2013   Glioma                                        0.75    0.46--1.22, *P*=0.0254      PFS           qRT-PCR             RNU6B                Kaplan--Meier            After
  Gao et al[@b23-ott-8-2709]         2013   Glioma                                        0.8     0.47--1.37, *P*=0.0074      OS            qRT-PCR             RNU6B                Kaplan--Meier            After
  Peurala et al[@b30-ott-8-2709]     2011   Breast cancer                                 0.88    0.65--1.88, *P*=0.573       5-year CSS    Microarray          --                   Cox model                Before
  Voortman et al[@b24-ott-8-2709]    2010   NSCLC                                         0.9     0.72--1.14, *P*=0.38        OS            qRT-PCR             U66                  Cox model                After
  Huang et al[@b29-ott-8-2709]       2014   Gastric cancer                                0.973   0.586--1.617, *P*=0.917     OS            qRT-PCR             miR-16               Cox model                Before
  Reimer et al[@b27-ott-8-2709]      2011   Ovarian cancer                                1.237   0.505--3.030, *P*=0.641     OS            qRT-PCR             TBP                  Cox model                --
  Reimer et al[@b27-ott-8-2709]      2011   Ovarian cancer                                1.334   0.597--2.978, *P*=0.482     PFS           qRT-PCR             TBP                  Cox model                --
  Genovese et al[@b26-ott-8-2709]    2012   Glioblastoma                                  1.37    0.99--1.89, *P*=0.0154      OS            qRT-PCR             --                   Kaplan--Meier            After
  Rücker et al[@b25-ott-8-2709]      2013   AML with complex karyotype                    1.47    1.06--2.03, *P*=0.02        OS            qRT-PCR             RNU6B                Cox model                After
  Rücker et al[@b25-ott-8-2709]      2013   AML with complex karyotype                    1.9     1.14--3.18, *P*=0.01        RFS           qRT-PCR             RNU6B                Cox model                After

**Abbreviations:** AML, acute myeloid leukemia; CI, confidence interval; Cox model, Mul Cox proportional hazard model; CSS, cancer-specific survival; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; DSS, disease-specific survival; EFS, event-free survival; HR, hazard ratio; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; miR-34a, microRNA-34a; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progress-free survival; RFS, recurrence-free survival; SCC, squamous cell carcinoma; --, unclear; qRT-PCR, qualitative real-time polymerase chain reaction.
